Supernus Pharmaceuticals, Inc.

As of June 30, 2026, Supernus Pharmaceuticals, Inc. carries a market capitalization of 2.37B, placing it among publicly traded companies globally. Its enterprise value stands at 2.08B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Supernus Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Supernus Pharmaceuticals, Inc. has 58.16M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 3.22, and the price-to-book ratio stands at 2.63.

These figures are as of June 30, 2026. The EV/Sales ratio of 2.87 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.08B versus a market cap of 2.37B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Supernus Pharmaceuticals, Inc. maintains a current ratio of 2.08, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.90, indicating elevated leverage, while an interest coverage ratio of -12.42 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Supernus Pharmaceuticals, Inc. posted a negative return on equity (ROE) of -10.49, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -7.82, reflecting losses generated across the asset base. The company generates approximately 966,598.91 in revenue per employee across its workforce of 752.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.55 indicates how many times Supernus Pharmaceuticals, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Supernus Pharmaceuticals, Inc. recorded an income tax benefit of -11.89M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -108.07M and -96.18M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Supernus Pharmaceuticals, Inc.'s stock has declined approximately 14.75% over the past 52 weeks. The 50-day moving average sits at 37.80, while the 200-day moving average is 41.01.

Over the twelve months ended June 30, 2026, Supernus Pharmaceuticals, Inc. generated 726.88M in revenue and converted that into -96.18M in net income, yielding earnings per share of -1.68. EBITDA reached -25.18M, while operating income came in at -48.49M.

As of June 30, 2026, Supernus Pharmaceuticals, Inc. holds 325.67M in cash and equivalents against 35.16M in total debt, resulting in a net debt position of -157.51M. Total book value stands at 902.63M, with working capital of 329.22M providing operational flexibility.

Supernus Pharmaceuticals, Inc. produced 17.43M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -983,837.20 in capital expenditures, free cash flow totaled 16.44M - equivalent to 0.29 per share.

Over the twelve months ended June 30, 2026, Supernus Pharmaceuticals, Inc. posted a gross margin of 88.07, reflecting its pricing power and cost economics. The operating margin of -6.67 and net profit margin of -13.23 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 0.70, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -1.16, meaning Supernus Pharmaceuticals, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Supernus Pharmaceuticals, Inc. has an Altman Z-Score of 6.17, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.